Sawgrass Asset Management LLC cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 35.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,875 shares of the company’s stock after selling 2,650 shares during the period. Sawgrass Asset Management LLC’s holdings in Omnicell were worth $249,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Omnicell by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,860,299 shares of the company’s stock worth $75,622,000 after purchasing an additional 97,345 shares during the last quarter. State Street Corp lifted its position in shares of Omnicell by 5.9% during the first quarter. State Street Corp now owns 849,845 shares of the company’s stock worth $34,545,000 after purchasing an additional 47,266 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Omnicell by 82.7% during the first quarter. Goldman Sachs Group Inc. now owns 88,926 shares of the company’s stock worth $3,615,000 after purchasing an additional 40,240 shares during the last quarter. State of Alaska Department of Revenue lifted its position in shares of Omnicell by 79.9% during the second quarter. State of Alaska Department of Revenue now owns 7,341 shares of the company’s stock worth $316,000 after purchasing an additional 3,261 shares during the last quarter. Finally, Aperio Group LLC lifted its position in shares of Omnicell by 84.7% during the second quarter. Aperio Group LLC now owns 29,730 shares of the company’s stock worth $1,281,000 after purchasing an additional 13,637 shares during the last quarter. Institutional investors own 97.93% of the company’s stock.

Omnicell, Inc. (OMCL) opened at $50.10 on Friday. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38. Omnicell, Inc. has a twelve month low of $31.85 and a twelve month high of $55.40.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The firm had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter last year, the company posted $0.40 earnings per share. Omnicell’s revenue was up 5.7% on a year-over-year basis. equities research analysts forecast that Omnicell, Inc. will post 0.12 EPS for the current year.

In other Omnicell news, VP Peter J. Kuipers sold 4,724 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $47.74, for a total value of $225,523.76. Following the transaction, the vice president now owns 40,544 shares of the company’s stock, valued at $1,935,570.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dan S. Johnston sold 14,613 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.81, for a total transaction of $698,647.53. Following the completion of the transaction, the executive vice president now directly owns 43,621 shares in the company, valued at approximately $2,085,520.01. The disclosure for this sale can be found here. Insiders sold 50,569 shares of company stock worth $2,493,822 in the last three months. 3.77% of the stock is currently owned by corporate insiders.

Several equities analysts have recently commented on the stock. BidaskClub cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $40.00 price target on shares of Omnicell in a research report on Sunday, July 30th. Craig Hallum reaffirmed a “buy” rating and set a $62.00 price target (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $55.00 price target on shares of Omnicell in a research report on Thursday, October 19th. Finally, Benchmark Co. increased their price target on shares of Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. Omnicell currently has an average rating of “Buy” and an average price target of $54.86.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/omnicell-inc-omcl-stake-decreased-by-sawgrass-asset-management-llc/1726999.html.

Omnicell Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.